Gene: MERTK
Official Full Name: MER proto-oncogene, tyrosine kinaseprovided by HGNC
Gene Summary: This gene is a member of the MER/AXL/TYRO3 receptor kinase family and encodes a transmembrane protein with two fibronectin type-III domains, two Ig-like C2-type (immunoglobulin-like) domains, and one tyrosine kinase domain. Mutations in this gene have been associated with disruption of the retinal pigment epithelium (RPE) phagocytosis pathway and onset of autosomal recessive retinitis pigmentosa (RP). [provided by RefSeq, Jul 2008]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO09890 | MERTK Knockout cell line (HCT 116) | Human | MERTK | 1:2~1:4 | Negative | Online Inquiry |
KO09891 | MERTK Knockout cell line (HEK293) | Human | MERTK | 1:3~1:6 | Negative | Online Inquiry |
KO09892 | MERTK Knockout cell line (A549) | Human | MERTK | 1:3~1:4 | Negative | Online Inquiry |
MERTK Gene Knockout Cell Lines are specialized cellular systems designed for the study of the MERTK gene, a critical component in various physiological and pathological processes, including immune regulation and cancer progression. These cell lines are engineered to lack functional MERTK protein, allowing researchers to investigate the gene's role without interference from its normal activity.
The primary function of MERTK gene knockout cell lines is to elucidate the signaling pathways and cellular mechanisms associated with MERTK in contexts ranging from apoptosis to autoimmunity. By providing a controlled environment where MERTK is absent, these cell lines enable scientists to assess the impact of MERTK modulation on cell behavior, responses to stimuli, and interactions with other immune cells. This is particularly important in understanding how MERTK contributes to cancer immune evasion and the resolution of inflammation.
In both research and clinical settings, these knockout cell lines serve as invaluable tools for drug discovery and development, especially in oncology and immunology. Their application spans from basic research into cellular pathways to translational studies focused on developing therapies that target MERTK-related pathways.
What sets our MERTK Gene Knockout Cell Lines apart from alternatives is their rigorous validation and characterization, ensuring that they are a reliable platform for experimental studies. Each line undergoes extensive quality control measures, including genotyping and protein analysis, to confirm the complete knockout of MERTK, thus providing consistency and reproducibility in research outcomes.
For researchers and clinicians keen on exploring innovative therapeutic strategies or unearthing novel biological insights, our MERTK Gene Knockout Cell Lines represent a significant asset. By leveraging our expertise in genetic engineering and cell line development, we offer additional support and resources to maximize the utility of these cell lines in your research.
With our commitment to advancing scientific inquiry through high-quality biological products, we aim to empower the research community to unravel the complexities of gene function and pave the way for breakthroughs in health and medicine.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.